; (2) the therapies currently available, and whether there is a need for additional innovation and development to produce therapies, to reduce the exposure of vulnerable populations in the United States to risk of disproportionate harm in epidemics and pandemics; and (3) whether the Secretary recommends providing the same incentives for the development and marketing of therapies described in paragraph (2) as is provided under the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. ) with respect to qualified infectious disease products designated under section 505E(d) of such Act ( 21 U.S.C. 355f(d) ).